 |
Recombinant Human Interleukin-21 (rIL-21) |
|---|---|
| Trade Name | |
| Orphan Indication | Stage II (T4), III or IV malignant melanoma |
| USA Market Approval | USA |
| USA Designation Date | 2005-10-04 00:00:00 |
| Sponsor | Zymo Genetics, Inc;1201 Eastlake Avenue East;Seattle, Washington, 98102 |
